EuroBiotech: More Articles of Note

(NS Newsflash/CC BY 2.0)

> Scancell raised £7.5 million ($10.7 million) to start a phase 2 trial of its cancer vaccine in combination with a checkpoint inhibitor. Statement

> Innate Pharma posted preliminary data on NKG2A monoclonal antibody monalizumab in combination with Erbitux. Eight of the 26 evaluable squamous cell carcinoma of the head and neck patients had partial responses. Release

> Autolus shared early data on its anti-GD2 CAR-T therapy. Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> BioCanCell raised $22.8 million to take its bladder cancer candidate into a pivotal trial. Release

> Adocia began a first-in-human trial of its pramlintide-human insulin fixed dose combination. Statement

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.